Semaglutide vs Liraglutide
Dosing, half-life, mechanism, benefits, and safety — side by side.
Semaglutide
FDA ApprovedGLP-1 receptor agonist for weight loss and type 2 diabetes management
Half-Life
~7 days
Route
SC
Dose
0.25-2.4 mg Weekly
MW
4113.58 Da
Liraglutide
FDA ApprovedGLP-1 agonist for diabetes and weight management
Half-Life
~13 hours
Route
SC
Dose
0.6-3.0 mg Daily
MW
3751.20 Da
Quick Reference
| Semaglutide | Liraglutide | |
|---|---|---|
| Category | N/A | N/A |
| Route | SC | SC |
| Typical Dose | 0.25-2.4 mg Weekly | 0.6-3.0 mg Daily |
| Frequency | Weekly | Daily |
| FDA Approved | Yes | Yes |
| WADA Status | Not banned | Not banned |
⏱ Pharmacokinetics
| Semaglutide | Liraglutide | |
|---|---|---|
| Half-Life | ~7 days | ~13 hours |
| Research Status | N/A | N/A |
| CAS Number | 910463-68-2 | 204656-20-2 |
Molecular
| Semaglutide | Liraglutide | |
|---|---|---|
| Molecular Weight | 4113.58 | 3751.20 |
| Molecular Formula | C187H291N45O59 | C172H265N43O51 |
| Sequence Length | 180 aa | 180 aa |
| Mechanism | GLP-1 receptor agonist that regulates appetite and glucose metabolism | GLP-1 receptor agonist for weight loss and diabetes management |
Key Benefits
| Semaglutide | Liraglutide | |
|---|---|---|
| Benefits | Significant weight loss; Blood sugar control; Reduced cardiovascular risk; Appetite suppression; Improved insulin sensitivity; GLP-1 agonist; Significant weight loss; Blood sugar control. | Proven weight loss; Blood sugar control; Cardiovascular benefits; Appetite reduction; Beta cell preservation |
Safety & Warnings
| Semaglutide | Liraglutide | |
|---|---|---|
| Safety Note | FDA approved for diabetes and obesity. Common side effects include nausea, vomiting, and diarrhea. | FDA approved for diabetes and obesity. Well-established safety profile. |
| Side Effects | Constipation; Interaction; Nausea; Diarrhea; Rare pancreatitis or thyroid risk; Interaction; GI adverse events; Discontinuation (GI) | Constipation; Rare pancreatitis; Diarrhea; Vomiting; Nausea; Mild-Moderate side effect; Mild-Moderate side effect; Mild side effect |
| Athlete Warning | Not WADA banned - safe for competitive athletes when used under medical supervision | Not WADA banned - safe for competitive athletes when used under medical supervision |
Which should you choose?
Liraglutide has a longer half-life (~~13 hours) than Semaglutide (~~7 days), which can mean less frequent dosing.
Semaglutide vs Liraglutide — FAQ
Which has a longer half-life: Semaglutide or Liraglutide?
Semaglutide has a half-life of ~~7 days while Liraglutide has a half-life of ~~13 hours. A longer half-life generally means less frequent dosing and more stable levels.
Can I stack Semaglutide and Liraglutide together?
Whether Semaglutide and Liraglutide can be stacked depends on their mechanisms and receptor targets. Use the stack compatibility checker to analyze synergies and conflicts before combining any peptides.
Which is better: Semaglutide or Liraglutide?
There is no universal "better" peptide — it depends on your goal. Semaglutide is GLP-1 receptor agonist that regulates appetite and glucose metabolism. Liraglutide is GLP-1 receptor agonist for weight loss and diabetes management. Choose based on your primary goal and research profile.
More Comparisons
Tirzepatide vs Semaglutide
Compare side-by-side →
BPC-157 vs TB-500
Compare side-by-side →
Retatrutide vs Tirzepatide
Compare side-by-side →
Semaglutide vs Retatrutide
Compare side-by-side →
Ipamorelin vs Sermorelin
Compare side-by-side →
CJC-1295 vs Sermorelin
Compare side-by-side →
MK-677 vs Ipamorelin
Compare side-by-side →
GHK-Cu vs AHK-Cu
Compare side-by-side →
Selank vs Semax
Compare side-by-side →
MOTS-c vs NAD+
Compare side-by-side →
PT-141 vs Melanotan-II
Compare side-by-side →
Tesamorelin vs CJC-1295
Compare side-by-side →
HGH vs MK-677
Compare side-by-side →